tetano
Editor, Senior Moderator
Res Pract Thromb Haemost
. 2020 Sep 25;10.1002/rth2.12436.
doi: 10.1002/rth2.12436. Online ahead of print.
Thrombo-inflammation response to Tocilizumab in COVID-19
Mansour Gergi[SUP] 1 [/SUP], Mary Cushman[SUP] 1 [/SUP], Benjamin Littenberg[SUP] 2 [/SUP], Ralph C Budd[SUP] 3 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease-19 (COVID-19) spans a wide spectrum of illness. Severe cases of COVID-19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that SARS-CoV-2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage.
Methods: With evidence of elevated levels of interleuking-6 (IL-6) in patients with severe COVID-19, we conducted a small pilot off-label compassionate care study of the IL-6 receptor inhibitor tocilizumab patients with severe COVID-19.
Results: Following a single infusion of tocilizumab in patients with severe manifested rapid declines in C-reactive protein (CRP), D-Dimer, and gradual rises in lymphocyte and platelet counts.
Conclusions: These findings suggest both pathophysiological mechanisms as well as clinical benefit that might be seen with IL-6 inhibition in severe COVID-19.
. 2020 Sep 25;10.1002/rth2.12436.
doi: 10.1002/rth2.12436. Online ahead of print.
Thrombo-inflammation response to Tocilizumab in COVID-19
Mansour Gergi[SUP] 1 [/SUP], Mary Cushman[SUP] 1 [/SUP], Benjamin Littenberg[SUP] 2 [/SUP], Ralph C Budd[SUP] 3 [/SUP]
Affiliations
- PMID: 33043232
- PMCID: PMC7537313
- DOI: 10.1002/rth2.12436
Abstract
Background: Coronavirus disease-19 (COVID-19) spans a wide spectrum of illness. Severe cases of COVID-19 can manifest inflammation in organs other than the lung, in tissues not known to support viral replication, and also in a hypercoagulable state. These observations have suggested that SARS-CoV-2 can provoke a hyperimmune response in some cases that could lead to secondary organ damage.
Methods: With evidence of elevated levels of interleuking-6 (IL-6) in patients with severe COVID-19, we conducted a small pilot off-label compassionate care study of the IL-6 receptor inhibitor tocilizumab patients with severe COVID-19.
Results: Following a single infusion of tocilizumab in patients with severe manifested rapid declines in C-reactive protein (CRP), D-Dimer, and gradual rises in lymphocyte and platelet counts.
Conclusions: These findings suggest both pathophysiological mechanisms as well as clinical benefit that might be seen with IL-6 inhibition in severe COVID-19.